Breaking News

ANI Pharma Expands Sofgen Development Pact

May 1, 2014

Sofgen to develop, manufacture generic soft gel drug product

ANI Pharmaceuticals, Inc. has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals for an undisclosed ANDA soft gel oral drug product. Sofgen will provide development, manufacture and regulatory submission of the drug, and ANI will be responsible for marketing and distribution in the U.S.
 
The branded product had annual U.S. sales of approximately $1 billion, according to IMS Health. Financial terms were not disclosed.
 
Arthur S. Przybyl, ANI's president and chief executive officer, said, "I am pleased to have expanded our collaboration with Sofgen through the addition of this second generic drug development project. ANI will continue to invest in both internal R&D efforts as well as external partnerships with high quality partners such as Sofgen."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers